Spots Global Cancer Trial Database for lorlatinib
Every month we try and update this database with for lorlatinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions | NCT02927340 | Non-Small Cell ... | Lorlatinib | 18 Years - | Massachusetts General Hospital | |
| Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib | NCT04753658 | Neuroblastoma | lorlatinib | 0 Years - | Pfizer | |
| A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China | NCT03909971 | Carcinoma, Non-... | Lorlatinib | 18 Years - | Pfizer | |
| Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment | NCT05167500 | Metastatic Non ... | Lorlatinib | 18 Years - | Fundación GECP | |
| A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis | NCT06410040 | ALK-positive No... Brain Metastase... Meningeal Metas... | Lorlatinib | 18 Years - | Sichuan Cancer Hospital and Research Institute | |
| A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors | NCT03546894 | Anaplastic Lymp... Carcinoma Non-s... | Brigatinib Alectinib Ceritinib Lorlatinib Any FDA Approve... | 18 Years - | Takeda | |
| Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) | NCT04621188 | Non Small Cell ... | Lorlatinib | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| PF-07284892 in Participants With Advanced Solid Tumors | NCT04800822 | Solid Tumor | PF-07284892 lorlatinib binimetinib cetuximab encorafenib | 18 Years - | Pfizer | |
| Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients | NCT04979988 | ALK-positive No... | Lortlatinib | 20 Years - | Pfizer | |
| Induction Lorlatinib in Stage III Non-small Cell Lung Cancer | NCT05740943 | Stage III NSCLC Surgery | Lorlatinib | 18 Years - 75 Years | Guangdong Provincial People's Hospital | |
| Lorlatinib Continuation Study | NCT05144997 | Non-Small-Cell ... NSCLC | Lorlatinib | 18 Years - | Pfizer | |
| Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib | NCT03727477 | Non-small Cell ... ALK Gene Rearra... ROS-1 Gene Rear... | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | ||
| PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer | NCT03439215 | Carcinoma, Non-... | Lorlatinib | 18 Years - | Fondazione Ricerca Traslazionale | |
| A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions | NCT02927340 | Non-Small Cell ... | Lorlatinib | 18 Years - | Massachusetts General Hospital | |
| Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer | NCT03737994 | Lung Non-Squamo... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Alectinib Brigatinib Carboplatin Ceritinib Cisplatin Crizotinib Ensartinib Lorlatinib Pemetrexed | 18 Years - | National Cancer Institute (NCI) | |
| Induction Lorlatinib in Stage III Non-small Cell Lung Cancer | NCT05740943 | Stage III NSCLC Surgery | Lorlatinib | 18 Years - 75 Years | Guangdong Provincial People's Hospital | |
| A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. | NCT05834348 | Non-Small Cell ... | lorlatinib crizotinib brigatinib ceritinib alectinib atezolizumab bevacizumab paclitaxel carboplatin docetaxel erlotinib gefitinib afatinib dacomitinib osimertinib pembrolizumab nivolumab entrectinib | 18 Years - 100 Years | Pfizer | |
| Lorlatinib Continuation Study | NCT05144997 | Non-Small-Cell ... NSCLC | Lorlatinib | 18 Years - | Pfizer | |
| A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors | NCT03546894 | Anaplastic Lymp... Carcinoma Non-s... | Brigatinib Alectinib Ceritinib Lorlatinib Any FDA Approve... | 18 Years - | Takeda | |
| Strata PATH™ (Precision Indications for Approved Therapies) | NCT05097599 | Cancer Advanced Solid ... | lorlatinib encorafenib + b... talazoparib sacituzumab gov... axitinib | 18 Years - | Strata Oncology | |
| Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib | NCT05948462 | Lung Cancer Non-small Cell ... | Lorlatinib Cisplatin or Ca... Pemetrexed | 18 Years - | SCRI Development Innovations, LLC | |
| A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis | NCT06410040 | ALK-positive No... Brain Metastase... Meningeal Metas... | Lorlatinib | 18 Years - | Sichuan Cancer Hospital and Research Institute | |
| Lorlatinib Combinations in Lung Cancer | NCT04292119 | Lung Cancer Anaplastic Lymp... ROS1 Rearrangem... Relapsed Cancer MET Amplificati... Resistant Cance... NSCLC | Lorlatinib Crizotinib Binimetinib TNO155 | 18 Years - | Massachusetts General Hospital | |
| Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India | NCT04541706 | Advanced Non-Sm... | Lorlatinib | 18 Years - | Pfizer | |
| Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients | NCT06361589 | ALK-positive No... Real World Stud... | Lorlatinib | 18 Years - | Sichuan Cancer Hospital and Research Institute | |
| Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients | NCT04127110 | Non Small Cell ... | Lorlatinib | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion | NCT06333899 | High Grade Glio... Diffuse Intrins... Anaplastic Astr... Infant Type Hem... Glioblastoma Glioblastoma Mu... WHO Grade III G... WHO Grade IV Gl... Diffuse Midline... | Lorlatinib Lorlatinib with... Lorlatinib with... Lorlatinib post... | 1 Year - 21 Years | Nationwide Children's Hospital | |
| A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib | NCT06378892 | Non Small Cell ... ALK Gene Mutati... | Lorlatinib | 18 Years - | Centro di Riferimento Oncologico - Aviano | |
| Study of Lorlatinib in ROS1 Rearranged NSCLC | NCT03612154 | Nonsmall Cell L... | Lorlatinib | 18 Years - | National Cancer Center, Korea | |
| Study of Lorlatinib in ROS1 Rearranged NSCLC | NCT03612154 | Nonsmall Cell L... | Lorlatinib | 18 Years - | National Cancer Center, Korea | |
| Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive | NCT03178071 | Non Small Cell ... | Lorlatinib | 18 Years - | Pfizer | |
| A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer | NCT05297890 | Advanced or Met... | Lorlatinib | 18 Years - | CStone Pharmaceuticals | |
| A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer | NCT06007937 | Non Small Cell ... Metastatic Recurrent | Lorlatinib Ramucirumab | 19 Years - | Memorial Sloan Kettering Cancer Center | |
| Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India | NCT04541706 | Advanced Non-Sm... | Lorlatinib | 18 Years - | Pfizer | |
| A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled | NCT06282991 | Non-Small Cell ... | Lorlatinib | 20 Years - | Pfizer | |
| A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis | NCT06410040 | ALK-positive No... Brain Metastase... Meningeal Metas... | Lorlatinib | 18 Years - | Sichuan Cancer Hospital and Research Institute | |
| Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer | NCT04111705 | Non Small Cell ... | Lorlatinib | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib | NCT04753658 | Neuroblastoma | lorlatinib | 0 Years - | Pfizer | |
| PF-07284892 in Participants With Advanced Solid Tumors | NCT04800822 | Solid Tumor | PF-07284892 lorlatinib binimetinib cetuximab encorafenib | 18 Years - | Pfizer | |
| Hepatic Impairment Study for Lorlatinib in Cancer Patients | NCT03726333 | Advanced Cancer... | lorlatinib lorlatinib lorlatinib lorlatinib lorlatinib | 18 Years - | Pfizer | |
| Hepatic Impairment Study for Lorlatinib in Cancer Patients | NCT03726333 | Advanced Cancer... | lorlatinib lorlatinib lorlatinib lorlatinib lorlatinib | 18 Years - | Pfizer | |
| A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions | NCT02927340 | Non-Small Cell ... | Lorlatinib | 18 Years - | Massachusetts General Hospital | |
| Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib | NCT04753658 | Neuroblastoma | lorlatinib | 0 Years - | Pfizer | |
| Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients | NCT06361589 | ALK-positive No... Real World Stud... | Lorlatinib | 18 Years - | Sichuan Cancer Hospital and Research Institute | |
| Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib | NCT05948462 | Lung Cancer Non-small Cell ... | Lorlatinib Cisplatin or Ca... Pemetrexed | 18 Years - | SCRI Development Innovations, LLC | |
| A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer | NCT05297890 | Advanced or Met... | Lorlatinib | 18 Years - | CStone Pharmaceuticals |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
